ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Kansas' MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1994
Meetings & Education
Financial Advocacy & Patient Assistance
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
Patient Advocacy Organizations
National Professional Organizations
KaSCO Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Ribociclib in Combination for Advanced, Metastatic Breast Cancer
On July 18, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corp.) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.
The FDA also approved ribociclib in combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.
Read the full FDA press release here.
Tweets by OSSatACCC